The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
Multiple Myeloma Hub
Claim This Podcastby Scientific Education Support
3.7(3 reviews)
90 episodes
Updated Weekly
Accepts GuestsHas SponsorsLocation 🇬🇧
36
Podcast Authority
BetaPoorBased on show quality, social media presence, reviews, charts, and more
Quality25
Social0
YouTube86
Engagement31
Podcast Overview
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
Language
🇺🇲
Publishing Since
5/15/2020
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
36
Podcast Authority
BetaPoorBased on show quality, social media presence, reviews, charts, and more
Quality25
Social0
YouTube86
Engagement31
6
Excellent Areas
2
Good Performance
11
Growth Opportunities
excellent
Episode Length
7 minutes
Performing excellently!
good
Show Notes Quality
3.0/5
Recommendations available
Unlock the full report to see detailed tips
needs improvement
Publishing Consistency
Every 28 days
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Multiple Myeloma Hub
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
May 29, 2026
What’s on the horizon for relapsed/refractory MM in 2026?
<p>The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What’s on the horizon for the treatment of relapsed/refractory multiple myeloma (MM) in 2026? </p><br><p>In this interview, Lonial provides an overview of recent and emerging developments in relapsed/refractory MM, highlighting advances in immune-based therapies and their potential to improve outcomes in the early relapsed setting. He also discusses how these approaches may influence treatment decision-making, the movement of novel therapies into earlier lines of treatment, and the broader implications for future disease management.</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
May 20, 2026
CELMoDs for the treatment of newly diagnosed and HR smoldering MM
<p>The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about the emerging role of cereblon E3 ligase modulators (CELMoDs) in newly diagnosed multiple myeloma (NDMM) and high-risk smoldering multiple myeloma.</p><br><p>During this interview, Richardson discusses the use of CELMoDs, particularly iberdomide, in earlier lines of therapy. Richardson reviews clinical data on activity and tolerability in newly diagnosed patients, including those who are transplant ineligible, as well as in combination with standard therapies. Richardson also explores the potential role of CELMoDs in maintenance strategies, risk-adapted approaches, and in high-risk smoldering multiple myeloma. </p><br><p>This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
May 13, 2026
CELMoDs for the treatment of relapsed/refractory MM
<p>The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about cereblon E3 ligase modulators (CELMoDs) for the treatment of relapsed/refractory multiple myeloma (RRMM). </p><br><p>During this interview, Richardson reviews clinical data on the activity of CELMoDs, including mezigdomide and iberdomide, in RRMM. Richardson highlights response rates observed in ongoing studies, including activity in heavily pretreated and B-cell maturation antigen (BCMA)-exposed patients, as well as in extramedullary disease. Richardson also discusses safety findings, including hematologic toxicity and infection risk, and outlines emerging data on combination strategies and ongoing phase III trials. </p><br><p>This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
90 total episodes available
Similar Podcasts
Discover related shows you might enjoy
HealthTree Podcast for Multiple Myeloma
HealthTree Podcast for MM
Medscape InDiscussion: Multiple Myeloma
Medscape
The Myeloma Minutes
Dr Jam Kothari & Dr Sally Moore
Blood Podcast
American Society of Hematology
OncLive® On Air
OncLive® On Air
Audio Journal of Oncology Podcast
Audio Medica News
All Ears English Podcast
Lindsay McMahon and Michelle Kaplan
The Daily
The New York Times
Deep-dive analytics for Multiple Myeloma Hub
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Multiple Myeloma Hub?
- How often does this podcast release new episodes?
This podcast updates weekly.
- Where can I listen to this podcast?
This podcast is available on 9 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.